News & Blog

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich’s Ataxia (PROVE-FA)

Webinar Recording: PTC Therapeutics June 2026

Community Letter: Update from PTC Therapeutics

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Press Release & Community Statement: PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

Press Release & Community Statement: PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich’s Ataxia

Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich’s Ataxia

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Vatiquinone (PTC-743)

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)